Serum miR-4530 sensitizes breast cancer to neoadjuvant chemotherapy by suppressing RUNX2

Xiaoxiao Wang, Fu-Gui Ye, Jie Zhang, Junjing Li, Qing-Xia Chen, Peiyang Lin, Chuangui Song

Cancer Management and Research · 2018 · 20 citations · 24 references

DOIFull text

Open access

Abstract

Our results revealed that elevated serum miR-4530 levels may sensitize breast cancer to taxane- and anthracycline-based NAC by suppressing RUNX2; therefore, this miRNA has the potential to be a new biomarker for predicting breast cancer chemosensitivity.

References

24